First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non–Small Cell Lung Cancer: Final Overall Survival Results From a Randomized Phase 3 Study

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2015.11.008
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2016English

P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Oncologist
Cancer ResearchMedicineOncology
2010English

Phase I and Pharmacokinetic Study of Pemetrexed Plus Cisplatin in Chemonaive Patients With Locally Advanced or Metastatic Malignant Pleural Mesothelioma or Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2009English

First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2010English

Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo After Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2011English

Pcn197 - Cost Utility Analysis of First-Line Paclitaxel With Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab Versus Pemetrexed With Carboplatin Followed by Maintenance Pemetrexed in Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer in Lebanon

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Phase II Study of Erlotinib Plus Tivantinib (ARQ 197) in Patients With Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Just After Progression on EGFR-TKI, Gefitinib or Erlotinib

ESMO Open
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy